Tegaserod in constipation associated with Parkinson disease

John Christopher Morgan, Kapil Dev Sethi

Research output: Contribution to journalArticle

28 Scopus citations


Impaired gastrointestinal motility and constipation are common problems in Parkinson disease (PD). Many patients with PD continue to experience constipation, despite multiple interventions (dietary modification, bulk-forming agents, stool softeners, and laxatives). Tegaserod is a 5-hydroxytryptamine type 4 agonist that stimulates gastrointestinal motility and is approved for the treatment of chronic idiopathic constipation. We report our experience with tegaserod in 5 patients with PD-associated constipation. Tegaserod was well tolerated and improved both bowel movement frequency and stool consistency in most of our patients. Further trials with tegaserod are warranted in PD-associated constipation.

Original languageEnglish (US)
Pages (from-to)52-54
Number of pages3
JournalClinical Neuropharmacology
Issue number1
StatePublished - Jan 1 2007


  • 5-HT agonist
  • Constipation
  • Parkinson disease
  • Tegaserod

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Tegaserod in constipation associated with Parkinson disease'. Together they form a unique fingerprint.

  • Cite this